

34. The molecule, according to claim 32, which comprises an amino acid sequence selected from the group consisting of :

AREEKHQKQLERQQLETEKKRRETVEREKEQM (SEQ ID NO. 1);
MREKEELMLRLQDY_(p)EEKTKKAERELSEQIQRALQ (SEQ ID NO. 2);
TEKKR (SEQ ID NO. 3);
TEKKRRETV (SEQ ID NO. 4);
TEKKRRETVER (SEQ ID NO. 5);
KKRRE (SEQ ID NO. 6);
KKRRETVE (SEQ ID NO. 7);
KKRRETVERE (SEQ ID NO. 8);
KKRRETVEREK (SEQ ID NO. 9);
KKRRETVEREKE (SEQ ID NO. 10);
KRRETVER (SEQ ID NO. 11);
KRRETVEREK (SEQ ID NO. 12);
KRRETVEREKE (SEQ ID NO. 13);
RRETV (SEQ ID NO. 14);
RETVEREKE (SEQ ID NO. 15);
EREKE (SEQ ID NO. 16);
EREKEQMMREKEEL (SEQ ID NO. 17);
KEELM (SEQ ID NO. 18);
KEELMLRLQDYEE (SEQ ID NO. 19);
KEELMLRLQDY_pEE (SEQ ID NO. 20);
EELMLRLQDYEE (SEQ ID NO. 21);
EELMLRLQDY_pEE (SEQ ID NO. 22);
ELMLRLQDYEE (SEQ ID NO. 23);
ELMLRLQDY_pEE (SEQ ID NO. 24);
MLRLQ (SEQ ID NO. 25);

QDYEE (SEQ ID NO. 26); and
QDYpEE (SEQ ID NO. 27).

35. The molecule, according to claim 34, which comprises:
AREEKHQKQLERQQLETEKKRRETVEREKEQM (SEQ ID NO. 1).

36. The molecule, according to claim 34, which comprises:
MREKEELMLRLQDY_(p)EEKTKKAERELSEQIQRALQ (SEQ ID NO. 2).

37. The molecule, according to claim 34, which comprises:
TEKKR (SEQ ID NO. 3).

38. The molecule, according to claim 34, which comprises:
TEKKRRETV (SEQ ID NO. 4).

39. The molecule, according to claim 34, which comprises:
TEKKRRETVER (SEQ ID NO. 5).

40. The molecule, according to claim 34, which comprises:
KKRRE (SEQ ID NO. 6).

41. The molecule, according to claim 34, which comprises:
KKRRETVE (SEQ ID NO. 7).

42. The molecule, according to claim 34, which comprises:
KKRRETVERE (SEQ ID NO. 8).

43. The molecule, according to claim 34, which comprises:
KKRRETVEREK (SEQ ID NO. 9).

44. The molecule, according to claim 34, which comprises:
KKRRETVEREKE (SEQ ID NO. 10).

45. The molecule, according to claim 34, which comprises:
KRRETVER (SEQ ID NO. 11).

46. The molecule, according to claim 34, which comprises:
KRRETVEREK (SEQ ID NO. 12).

47. The molecule, according to claim 34, which comprises:
KRRETVEREKE (SEQ ID NO. 13).

48. The molecule, according to claim 34, which comprises:
RRETV (SEQ ID NO. 14).

49. The molecule, according to claim 34, which comprises:
RETVEREKE (SEQ ID NO. 15).

50. The molecule, according to claim 34, which comprises:
EREKE (SEQ ID NO. 16).

51. The molecule, according to claim 34, which comprises:
EREKEQMMREKEEL (SEQ ID NO. 17).

52. The molecule, according to claim 34, which comprises:
KEELM (SEQ ID NO. 18).

53. The molecule, according to claim 34, which comprises:
KEELMLRLQDYEE (SEQ ID NO. 19).

54. The molecule, according to claim 34, which comprises:
KEELMLRLQDYpEE (SEQ ID NO. 20).

55. The molecule, according to claim 34, which comprises:
EELMLRLQDYEE (SEQ ID NO. 21).

56. The molecule, according to claim 34, which comprises:
EELMLRLQDYpEE (SEQ ID NO. 22).

57. The molecule, according to claim 34, which comprises:
ELMLRLQDYEE (SEQ ID NO. 23).

58. The molecule, according to claim 34, which comprises:
ELMLRLQDYpEE (SEQ ID NO. 24).

59. The molecule, according to claim 34, which comprises:
MLRLQ (SEQ ID NO. 25).

60. The molecule, according to claim 34, which comprises:
QDYEE (SEQ ID NO. 26).

61. The molecule, according to claim 34, which comprises:
QDYpEE (SEQ ID NO. 27).

62. A method for upregulating the immune system wherein said method comprises administering, to a patient in need of such upregulation, an effective amount of a molecule which binds to the Hephreceptor.

63. The method, according to claim 62, wherein said molecule is charged.

64. The method, according to claim 62, wherein said molecule comprises an amino acid sequence identical to all or part of the Hephreceptor.

65. The method, according to claim 64, wherein said molecule comprises between 5 and 13 amino acids which are identical to the Hephreceptor.

66. The method, according to claim 64, wherein said molecule comprises an amino acid sequence selected from the group consisting of :

AREEKHQKQLERQQLETEKKRRETVEREKEQM (SEQ ID NO. 1);
MREKEELMLRLQDY_(p)EEKTKKAERELSEQIQRALQ (SEQ ID NO. 2);
TEKKR (SEQ ID NO. 3);
TEKKRRETV (SEQ ID NO. 4);
TEKKRRETVER (SEQ ID NO. 5);
KKRRE (SEQ ID NO. 6);
KKRRETVE (SEQ ID NO. 7);
KKRRETVERE (SEQ ID NO. 8);
KKRRETVEREK (SEQ ID NO. 9);
KKRRETVEREKE (SEQ ID NO. 10);

KRRETVER (SEQ ID NO. 11);
KRRETVEREK (SEQ ID NO. 12);
KRRETVEREKE (SEQ ID NO. 13);
RRETV (SEQ ID NO. 14);
RETVEREKE (SEQ ID NO. 15);
EREKE (SEQ ID NO. 16);
EREKEQMMREKEEL (SEQ ID NO. 17);
KEELM (SEQ ID NO. 18);
KEELMLRLQDYEE (SEQ ID NO. 19);
KEELMLRLQDYpEE (SEQ ID NO. 20);
EELMLRLQDYEE (SEQ ID NO. 21);
EELMLRLQDYpEE (SEQ ID NO. 22);
ELMLRLQDYEE (SEQ ID NO. 23);
ELMLRLQDYpEE (SEQ ID NO. 24);
MLRLQ (SEQ ID NO. 25);
QDYEE (SEQ ID NO. 26); and
QDYpEE (SEQ ID NO. 27).

67. A method for treating tumors wherein said method comprises administering, to a patient in need of such treatment, an effective amount of a molecule which binds to at least one domain of the Heparin Receptor.

68. The method, according to claim 67, wherein said molecule is charged.

69. The method, according to claim 67, wherein said molecule comprises an amino acid sequence identical to all or part of the Heparin Receptor.

70. The method, according to claim 69, wherein said molecule comprises between 5 and 13 amino acids which are identical to the Hepreceptor.

71. The method, according to claim 67, wherein said molecule comprises an amino acid sequence selected from the group consisting of :

AREEKHQKQLERQQLETEKKRRETVEREKEQM (SEQ ID NO. 1);
MREKEELMLRLQDY_(p)EEKTKKAERELSEQIQRALQ (SEQ ID NO. 2);
TEKKR (SEQ ID NO. 3);
TEKKRRETV (SEQ ID NO. 4);
TEKKRRETVER (SEQ ID NO. 5);
KKRRE (SEQ ID NO. 6);
KKRRETVE (SEQ ID NO. 7);
KKRRETVERE (SEQ ID NO. 8);
KKRRETVEREK (SEQ ID NO. 9);
KKRRETVEREKE (SEQ ID NO. 10);
KRRETVER (SEQ ID NO. 11);
KRRETVEREK (SEQ ID NO. 12);
KRRETVEREKE (SEQ ID NO. 13);
RRETV (SEQ ID NO. 14);
RETVEREKE (SEQ ID NO. 15);
EREKE (SEQ ID NO. 16);
EREKEQMMREKEEL (SEQ ID NO. 17);
KEELM (SEQ ID NO. 18);
KEELMLRLQDYEE (SEQ ID NO. 19);
KEELMLRLQDY_pEE (SEQ ID NO. 20);
EELMLRLQDYEE (SEQ ID NO. 21);
EELMLRLQDY_pEE (SEQ ID NO. 22);

ELMLRLQDYEE (SEQ ID NO. 23);
ELMLRLQDYpEE (SEQ ID NO. 24);
MLRLQ (SEQ ID NO. 25);
QDYEE (SEQ ID NO. 26);
QDYpEE (SEQ ID NO. 27); and
TEKKRRETVEREKE (SEQ ID NO. 28).

72. A method for treating HIV wherein said method comprises administering, to a patient in need of such treatment, an effective amount of a molecule which binds to at least one domain of the Hepreceptor, and wherein said molecule is not Hep 1.

73. The method, according to claim 72, wherein said molecule is charged.

74. The method, according to claim 72, wherein said molecule comprises an amino acid sequence identical to all or part of the Hepreceptor.

75. The method, according to claim 74, wherein said molecule comprises between 5 and 13 amino acids which are identical to the Hepreceptor.

76. The method, according to claim 72, wherein said molecule comprises an amino acid sequence selected from the group consisting of :

AREEKHQKQLERQQLETEKKRRETVEREKEQM (SEQ ID NO. 1);
MREKEELMLRLQDY_(p)EEKTKKAERELSEQIQRALQ (SEQ ID NO. 2);
TEKKR (SEQ ID NO. 3);
TEKKRRETV (SEQ ID NO. 4);
TEKKRRETVER (SEQ ID NO. 5);
KKRRE (SEQ ID NO. 6);

KKRRETVE (SEQ ID NO. 7);
KKRRETVERE (SEQ ID NO. 8);
KKRRETVEREK (SEQ ID NO. 9);
KKRRETVEREKE (SEQ ID NO. 10);
KRRETVER (SEQ ID NO. 11);
KRRETVEREK (SEQ ID NO. 12);
KRRETVEREKE (SEQ ID NO. 13);
RRETV (SEQ ID NO. 14);
RETVEREKE (SEQ ID NO. 15);
EREKE (SEQ ID NO. 16);
EREKEQMMREKEEL (SEQ ID NO. 17);
KEELM (SEQ ID NO. 18);
KEELMLRLQDYEE (SEQ ID NO. 19);
KEELMLRLQDYpEE (SEQ ID NO. 20);
EELMLRLQDYEE (SEQ ID NO. 21);
EELMLRLQDYpEE (SEQ ID NO. 22);
ELMLRLQDYEE (SEQ ID NO. 23);
ELMLRLQDYpEE (SEQ ID NO. 24);
MLRLQ (SEQ ID NO. 25);
QDYEE (SEQ ID NO. 26); and
QDYpEE (SEQ ID NO. 27).